Table 3.
Univariate Analysis of Multidrug Resistance Acquired During Treatment Among All Case Patients With Initial Drug Susceptibility Test Results for Isoniazid and Rifampicin
| Characteristic | Acquired MDR Tuberculosis Following Susceptible Initial Result (n = 1573), ORa (95% CI) | P Value | Acquired MDR Tuberculosis Following Isoniazid Monoresistance (n = 202), ORa (95% CI) | P Value | Any Acquired MDR Tuberculosis (n = 1792), ORa (95% CI) | P Value |
|---|---|---|---|---|---|---|
| No. of cases | 16 | 27 | 49 | |||
| Age, per y | 0.99 (.96–1.02) | .38 | 0.99 (.96–1.01) | .23 | 0.98 (.97–1.00) | .07 |
| Mexican-born | 3.0 (1.12–8.04) | .03 | 0.64 (.24–1.68) | .36 | 1.28 (.73–2.26) | .39 |
| Extrapulmonary disease | 3.15 (1.14–8.75) | .03 | 1.43 (.45–4.57) | .55 | 1.77 (.91–3.44) | .09 |
| Cavitary chest radiograph | 0.36 (.039–1.60) | .083 | 1.68 (.71–3.94) | .12 | 0.91 (.47–1.74) | .39 |
| HIV infection | 8.44 (3.12–22.8) | <.0001 | 4.19 (1.29–13.6) | .017 | 4.26 (2.30–7.90) | <.0001 |
| Death during treatment | 3.79 (1.2–11.9) | .02 | 14.3 (4.25–48.2) | <.0001 | 5.34 (2.84–10.1) | <.0001 |
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; MDR, multidrug-resistant; OR, odds ratio.
a Unadjusted odds ratio.